Onze Lieve Vrouwe Gasthuis is a major clinical hospital situated near Oosterpark in Amsterdam in the Netherlands. Founded in 1898, it is now part of OLVG, a network of hospitals formed by the merger of the Onze Lieve Vrouwe Gasthuis with the former Sint Lucas Andreas hospital, and is now known as OLVG, West Location.

During the past decade, OLVG Oost conducted 13 clinical trials. In the 10-year time frame, 13 clinical trials started and 4 clinical trials were completed, i.e. on average, 30.8% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 4 clinical trials were completed. i.e. 66.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "OLVG Oost" #1 sponsor was "Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)" with 3 trials, followed by "B.C. van Jaarsveld" with 1 trials sponsored, "Bayer" with 1 trials sponsored, "Charite University, Berlin, Germany" with 1 trials sponsored and "Clementia Pharmaceuticals Inc." with 1 trials sponsored. Other sponsors include 2 different institutions and companies that sponsored additional 12 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "OLVG Oost" #1 collaborator was "Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)" with 1 trials as a collaborator, "Admiraal de Ruyter Hospital" with 1 trials as a collaborator, "Alrijne Hospital" with 1 trials as a collaborator, "Amphia Hospital" with 1 trials as a collaborator and "Aspen Pharma" with 1 trials as a collaborator. Other collaborators include 40 different institutions and companies that were collaborators in the rest 50 trials.

According to Clinical.Site data, the most researched conditions in "OLVG Oost" are "Colitis, Ulcerative" (3 trials), "Acute Myocardial Infarction" (1 trials), "Chronic Kidney Disease" (1 trials), "Colorectal Cancer" (1 trials) and "Coronary Artery Disease" (1 trials). Many other conditions were trialed in "OLVG Oost" in a lesser frequency.

Most popular intervention types in "OLVG Oost" are "Drug" (11 trials), "Combination Product" (1 trials), "Diagnostic Test" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (6 trials), "Adalimumab" (1 trials), "Adalimumab placebo" (1 trials), "Apabetalone" (1 trials) and "Atezolizumab" (1 trials). Other intervention names were less common.

The vast majority of trials in "OLVG Oost" are 13 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "OLVG Oost". undefined are not yet recruiting, 5 are recruiting, 2 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 3 completed trials in OLVG Oost, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in OLVG Oost, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 7 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 1 trials that are defined as “Not Applicable".